MDF's Chief Scientific Officer, Dr. Andy Rohrwasser, provides a summary of "Natural history of cardiac involvement in myotonic dystrophy type 1 – Emphasis on the need for lifelong follow-up", PEtri et al International Journal of Cardiology 2024.

@media only screen and (max-width: 767px) { .screen-placer { float: none; padding-left:0px;" } }

Entering the University of Rochester for graduate school, Ms. Hamazaki sought translational research experience with mouse models, influenced by her time in the pharmaceutical industry during the COVID-19 pandemic. Exposure to myotonic dystrophy research at Regeneron and the collaborative environment at the University of Rochester solidified her interest in myotonic dystrophy research. Post-graduate school, Ms. Hamazaki aspires to apply her skills to patient-focused myotonic dystrophy research, driven by the desire to contribute impactful research benefiting the patient community.

MDF is proud to report on its sponsorship and participation in the prestigious 14th International Myotonic Dystrophy Consortium Meeting (IDMC-14) held in Nijmegen!